Metraipolis › archive › dc_fb99e2dd6641

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from… — Europe PMC PMID:41275209

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41275209
DOI
10.1186/s40164-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-11-08T08:26:42.364Z
SHA-256 of the archived text
e37df693459ad13315585a3527f2b0b5f413e5f27cfd3463c9c7939589af7342
Stable URL of this page
https://metraipolis.com/documento/dc_fb99e2dd6641

How to cite

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from… — Europe PMC PMID:41275209 — Europe PMC (en), https://europepmc.org/article/MED/41275209 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fb99e2dd6641 (Metraipolis archive dc_fb99e2dd6641, sha256 e37df693459ad13315585a3527f2b0b5f413e5f27cfd3463c9c7939589af7342)
BibTeX
@misc{dcfb99e2dd6641,
  title = {Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from… — Europe PMC PMID:41275209},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41275209},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fb99e2dd6641; sha256 e37df693459ad13315585a3527f2b0b5f413e5f27cfd3463c9c7939589af7342},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41275209. Agents can read the archived copy with the MCP tool read_document.